The cost of GLP-1 therapy is one of the most common questions we receive, and it is a fair one. In Western markets, brand-name GLP-1 medications like Ozempic or Mounjaro cost USD 800 to 1,400 per month without insurance, pricing out most patients. In India, the situation is different but not without its challenges.
Here is a transparent breakdown of what GLP-1 therapy actually costs, and where the value lies.
Why Brand-Name GLP-1 Is Expensive Everywhere
Brand-name GLP-1 medications carry a significant price premium for several reasons:
- Research and development recovery: The clinical trial programs for semaglutide and tirzepatide cost hundreds of millions of dollars
- Patent protection: Brand-name manufacturers hold exclusive rights for years after approval
- Distribution and supply chain costs: Particularly for imported medications in India
- Brand premium: Marketing and brand positioning add additional cost
None of these factors relate to the efficacy of the active molecule. The semaglutide in Ozempic is the same molecule as in physician-supervised compounded semaglutide programs.
Cost Breakdown in India
Brand-Name Ozempic (Imported)
Where available in India, imported Ozempic typically costs approximately INR 25,000 to 50,000 per month depending on dose. Availability is inconsistent, and the supply chain is not always reliable.
Brand-Name Mounjaro (Tirzepatide, Imported)
Similar pricing range to Ozempic, with comparable availability challenges.
Physician-Supervised Compounded GLP-1 (via Longegra)
Compounded GLP-1 programs through Longegra are significantly more accessible. The total cost depends on the specific peptide, dose level, and whether the program includes biomarker testing packages, but is a fraction of brand-name import pricing.
What Is Included in the Longegra Program Cost
Unlike purchasing medication alone, a Longegra program is a complete clinical service. The pricing includes:
- Initial biomarker panel (blood tests required before prescription)
- Physician consultation to review results and design your protocol
- Prescription and supply of pharmaceutical-grade compounded peptide
- Ongoing monthly clinical support and check-in calls
- Three-month and six-month re-test panels to confirm progress
- Direct physician access for any side effects or concerns between appointments
When you account for all the components a self-managed approach would require (lab tests, physician consultations, pharmacy orders, injections supplies), the all-inclusive model is both more comprehensive and better value.
The Cost of Not Treating Metabolic Disease
There is another dimension to the cost question that is worth considering. The downstream costs of untreated obesity, pre-diabetes, and metabolic syndrome in India are substantial:
- Type 2 diabetes management: ongoing medication, specialist visits, monitoring supplies
- Cardiovascular disease: hospitalisation, interventional cardiology, long-term cardiac medications
- Fatty liver disease: hepatology management, eventual cirrhosis risk
- Reduced productivity, quality of life, and earning capacity
GLP-1 therapy at current evidence-based doses significantly reduces the risk of all of these outcomes. The one-year cost of a supervised GLP-1 program compares favourably to even a single hospitalisation for a cardiovascular event.
Is GLP-1 Covered by Insurance in India?
Currently, GLP-1 therapy for weight loss is not typically covered by Indian health insurance plans. Prescription GLP-1 for type 2 diabetes management may have partial coverage under some corporate health plans. We recommend checking directly with your insurer.
Longegra provides documentation of your clinical program that may support reimbursement claims where applicable.
Frequently Asked Questions (FAQs)
"Research grade" peptides sold online without a prescription are not pharmaceutical-grade products. They carry real risks of impurity, incorrect dosing, and absence of clinical oversight. The apparent cost saving comes at the cost of safety and clinical legitimacy.
